Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Rescue Therapy

  • Home
  • Rescue Therapy
Inebilizumab Significantly Reduces Exacerbations and Need for Rescue Therapy in Generalized Myasthenia Gravis: Insights from the Phase 3 MINT Trial
Posted inAllergy & Immunology Neurology news

Inebilizumab Significantly Reduces Exacerbations and Need for Rescue Therapy in Generalized Myasthenia Gravis: Insights from the Phase 3 MINT Trial

Posted by MedXY By MedXY 08/14/2026
The MINT trial demonstrates that inebilizumab markedly lowers exacerbation rates and rescue therapy use in AChR+ and MuSK+ generalized myasthenia gravis patients undergoing corticosteroid tapering.
Read More
  • Clinical Insights into Lipoid Proteinosis: Efficacy and Long-Term Outcomes of Microlaryngosurgery
  • Advancing Surgical Excellence: An Objective Tool Validates Performance in Robotic and Laparoscopic Hysterectomy
  • Unraveling Lesion Progression in Adult Cerebral Adrenoleukodystrophy to Inform Personalized Management
  • Evaluating the Long-Term Impact of Electrical Stimulation Biofeedback Combined with Pelvic Floor Muscle Training for Postpartum Pelvic Organ Prolapse
  • Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in